With its lead product, a deuterium-tweaked version of tetrabenazine for hyperkinetic movement disorders, in Phase III testing in chorea associated with Huntington’s disease (HD), orphan drug company Auspex Pharmaceuticals Inc. added its name to the initial public offering (IPO) roster.